论文部分内容阅读
癌症居世界疾病死亡率的第二位,抗癌药物的研究和开发当然为全世界所关注。随着干扰素,TNF、生物“导弹”的出现,对传统抗癌疗法及药物市场的冲击波已可预见,专家们预测2000年后,人类将攻破癌症关。 (一) 新抗癌药物的开发及国外市场近年来所开发的抗癌药物,大多数是已知药物的衍生物。阿霉素具有广泛的抗癌活性,不仅对血液系统的肿瘤有效,而且对乳腺癌,甲状腺癌、软组织肉瘤、消化道癌和肺癌等也有效,但遗憾的是该药对骨髓和心脏的毒性令
Cancer ranks second in the mortality rate of disease in the world. The research and development of anti-cancer drugs is of course concern to the world. With the advent of interferon, TNF, and biological “missiles,” shockwaves for traditional anti-cancer therapies and drug markets are predictable. Experts predict that after 2000, humans will break the cancer barrier. (a) The development of new anticancer drugs and the development of anticancer drugs in foreign markets in recent years are mostly derivatives of known drugs. Doxorubicin has a wide range of anti-cancer activity and is effective not only for hematological tumors, but also for breast cancer, thyroid cancer, soft tissue sarcoma, digestive tract cancer, and lung cancer, but unfortunately it is toxic to bone marrow and heart. make